Delcath Systems
New York
About Delcath Systems
Delcath Systems is an interventional oncology company that focuses on the treatment of metastatic liver cancer. Its proprietary product Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS) is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 101 – 250
- Estimated revenue: $10K – $50K
- Total funding: $292.9M
- Funding stage: IPO
- Last round: Post-IPO Equity (Dec 2024)
- Ticker: otcqb:DCTH
- Website: delcath.com
- Phone: 2124892102
Industries & Categories
Biotechnology, Health Care, Oncology, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/delcath-systems-105392 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.